Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai leads the “REVERSE-IT” trial.

Trial led by Mount Sinai researcher could save lives for patients in need of urgent surgery, invasive procedures, or experiencing major bleeding

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients with acute coronary syndromes, prior heart attack, stroke, and coronary artery disease.

Those are the findings from a multi-center international clinical trial analyzing bentracimab, the first experimental treatment of its kind. The “REVERSE-IT” trial results were presented Saturday, March 29, in a Late Breaking Clinical Trial Session at the American Academy of Cardiology Scientific Session (ACC.25) in Chicago.

Learn More